Navigation Links
Gentium's Defibrotide Seen as Active in Multiple Myeloma

NEW YORK--(BUSINESS WIRE)--Jun 27, 2007 - Gentium S.p.A. (Nasdaq: GENT) announced the presentation of both clinical and preclinical data that support the safety, activity, synergy and potential mechanism of action of Defibrotide in combination with anticancer therapy in multiple myeloma. Investigators presented both an update from the Company's ongoing Phase I/II clinical trial for patients with refractory or relapsed multiple myeloma with Defibrotide in combination with chemotherapy, as well as a pre-clinical study demonstrating the downregulation of a key regulatory enzyme supporting a novel mechanism of action for Defibrotide in myeloma. Data from both studies was presented at the XI International Myeloma Workshop in Kos, Greece, 25-30 June, 2007.

In the first study, investigators led by Dr Antonio Palumbo of The Italian Multiple Myeloma Study Group, presented data from an ongoing multi-center, phase I/II clinical trial for relapsed or refractory multiple myeloma patients. This study is being conducted in an effort to define the maximum tolerated dose (MTD), safety and potential efficacy of the combination of melphalan, prednisone, thalidomide and Defibrotide (MPTD). Nineteen patients, who received at least three cycles of MPTD were evaluable for toxicity and response. Three escalating dose levels of Defibrotide were evaluated in combination with standard doses of melphalan, prednisone and thalidomide. No other thromboprophylaxis was administered. After a median of 3 cycles, the major response rate, including complete and partial remission was 53% (1CR, 1nCR and 7PR). Responses were seen in all three Defibrotide dose levels. Follow up remains limited and the durability of response appears favorable. MTD was not reached in any cohort. Hematological toxicities (greater than/equal to Grade 3) included neutropenia (47%), thrombocytopenia (10%), anemia (21%), non-hematological toxicities greater than/equal to grade 3 were observed in less than 5% of patients. Impor
'"/>




Page: 1 2 3

Related medicine technology :

1. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
2. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
3. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
4. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
5. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
6. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
7. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
8. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
9. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
10. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
11. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gentium Defibrotide Seen Active Multiple Myeloma
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... and GAITHERSBURG, Md., May 30, 2012   Life Technologies ... OpGen, Inc ., a commercial stage whole genome analysis ... agreement to develop systems, technologies and applications intended to ... the public health and infectious disease markets. ...
... of Opioid Management is presenting the ... the Joseph B. Martin Conference Center at Harvard Medical School. ... clinical application, and compliance, will address the proper use, and ... According to a recent National Survey on Drug Use and ...
Cached Medicine Technology:Life Technologies and OpGen Sign Collaborative Agreement to Leverage Ion Torrent and Whole Genome Mapping Technologies 2Life Technologies and OpGen Sign Collaborative Agreement to Leverage Ion Torrent and Whole Genome Mapping Technologies 3Life Technologies and OpGen Sign Collaborative Agreement to Leverage Ion Torrent and Whole Genome Mapping Technologies 4Unique Conference Tackles Opioid Abuse Epidemic 2
(Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
(Date:4/24/2014)... Orleans, LA The National Science Foundation has ... Research Experiences for Undergraduates (REU) Site grant in ... the training of undergraduates from diverse social and ... the New Orleans area. The project will ... the summers of 2014-16. It will be ...
(Date:4/24/2014)... research led by a scientist at the University of ... element in the development of the nervous system may ... breast cancer., A research team, led by Dr ... Department of Biology at York, has studied how voltage-gated ... These channels are found in the membranes of excitable ...
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
Breaking Medicine News(10 mins):Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2
... Elsevier announced today that major global ... Germany, has signed an agreement to purchase EMBASE ... first time, EMBASE Classic is a fully digitized ... Journals published between 1947 and 1973. Covering ...
... randomized, controlled, multi-center trial has found that cardiac ... uptake during exercise testing, the trial,s primary endpoint, ... mechanical problems that disrupt the heart,s normal rhythm ... on EKG. , The Resynchronization Therapy in Narrow ...
... OSTE ) announced today that third quarter 2007 revenue ... revenue of $23.4,million. Revenue from Osteotech,s "core" DBM and ... months ended September 30,2007 as compared to revenue of ... of 2006. Gross margin improved to 55% in the ...
... Nov. 6 EntreMed, Inc.,(Nasdaq: ENMD ), ... of cancer and inflammatory diseases, today,reported results for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) Revenues ... $3,023,000 for the comparable period a year ago. ...
... (Pink Sheets: BIEL), announced today that Michael Seidenman,R. ... President of Sales. Mr. Seidenman is a ... versed in electro medicine devices. He brings to,the ... sales,management. Mr. Seidenman has launched many new products, ...
... Nov. 6 /PRNewswire-FirstCall/ - Response Biomedical,Corporation (TSX-V: RBM, ... Stock Exchange (TSX) has conditionally approved the Company,s,application ... Listing on the TSX,will be subject to the ... Company will issue a news release when final ...
Cached Medicine News:Health News:EMBASE Classic makes inroads into pharmaceutical industry 2Health News:Study puts brakes on extending indications for cardiac resynchronization therapy 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 3Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 4Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 5Health News:EntreMed Reports Third Quarter 2007 Financial Results 2Health News:EntreMed Reports Third Quarter 2007 Financial Results 3Health News:EntreMed Reports Third Quarter 2007 Financial Results 4Health News:EntreMed Reports Third Quarter 2007 Financial Results 5Health News:BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales 2Health News:Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange 2Health News:Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange 3
... offers state-of-the-art quality in an instrument of ... durability. Low profile cutting tips allow access ... I instruments are available in just about ... required for large and small joint arthroscopic ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ... angle required for large and small joint ...
Medicine Products: